Praxis Precision MedicinesPRAX
PRAX
0
Funds holding %
of 6,780 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
133% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 15
20% more call options, than puts
Call options by funds: $24M | Put options by funds: $20M
18% more funds holding
Funds holding: 113 [Q2] → 133 (+20) [Q3]
2% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 43
0% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 5 (+0) [Q3]
2.55% less ownership
Funds ownership: 108.77% [Q2] → 106.22% (-2.55%) [Q3]
55% less capital invested
Capital invested by funds: $2.42B [Q2] → $1.09B (-$1.33B) [Q3]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$120
55%
upside
Avg. target
$140
82%
upside
High target
$163
111%
upside
9 analyst ratings
9 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Douglas Tsao 58% 1-year accuracy 68 / 118 met price target | 55%upside $120 | Buy Reiterated | 7 Nov 2024 |
Needham Ami Fadia 49% 1-year accuracy 52 / 106 met price target | 95%upside $151 | Buy Reiterated | 7 Nov 2024 |
Oppenheimer Francois Brisebois 63% 1-year accuracy 17 / 27 met price target | 111%upside $163 | Outperform Maintained | 31 Oct 2024 |
HC Wainwright & Co. Douglas Tsao 58% 1-year accuracy 68 / 118 met price target | 55%upside $120 | Buy Reiterated | 10 Sept 2024 |
Needham Ami Fadia 49% 1-year accuracy 52 / 106 met price target | 95%upside $151 | Buy Reiterated | 5 Sept 2024 |
Financial journalist opinion
Based on 5 articles about PRAX published over the past 30 days
Neutral
GlobeNewsWire
1 hour ago
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences in December 2024.
Neutral
GlobeNewsWire
3 weeks ago
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024.
Neutral
Seeking Alpha
3 weeks ago
Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript
Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Dan Ferry - IR, LifeSci Communications Marcio Souza - President & CEO Tim Kelly - CFO Conference Call Participants Ritu Baral - TD Cowen Yasmeen Rahimi - Piper Sandler Joon Lee - Truist Securities Francois Brisebois - Oppenheimer Yatin Suneja - Guggenheim Douglas Tsao - H.C. Wainwright Kambiz Yazdi - Jefferies Ami Fadia - Needham Joel Beatty - Baird Laura Chico - Wedbush Securities Operator Good day and thank you for standing by.
Negative
Zacks Investment Research
3 weeks ago
Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.75 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $2.70 per share a year ago.
Neutral
GlobeNewsWire
3 weeks ago
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025
Neutral
GlobeNewsWire
1 month ago
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024.
Positive
Zacks Investment Research
1 month ago
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Zacks Investment Research
2 months ago
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
Neutral
GlobeNewsWire
2 months ago
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the International League Against Epilepsy (ILAE) 15th European Epilepsy Congress (EEC), being held from September 7 to 11, 2024 in Rome, Italy.
Neutral
GlobeNewsWire
2 months ago
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period Over 30% of patients achieved seizure freedom status while on relutrigine Meaningful gains observed in alertness, communication and seizure severity 75% reduction in median seizure rate seen for patients in the long-term extension Registrational phase of the EMBOLD study for SCN2A and 8A initiated BOSTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today shared positive topline results for its Phase 2, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients.
Charts implemented using Lightweight Charts™